MS4A1 and diffuse large B-cell lymphoma: In 2022, Mosunetuzumab (CD20 × CD3) was the first approved BsAb for r/r FL, followed by the approval of Glofitamab (CD20 × CD3) and Epcoritamab (CD20 × CD3) for the treatment of r/r DLBCL [13,79].